Jay Pathmanathan
Research Subjects
Jay Pathmanathan has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
Jacob Donoghue
Beacon Biosignals, Inc., Boston, MA, United States
7 shared publicationsKolia Sadeghi
Beacon Biosignals Inc. , Boston, MA 02210
4 shared publications- Jacob Donoghue
Beacon Biosignals, Boston, MA, USA
3 shared publications M Brandon Westover
Beacon Biosignals , Boston, MA
3 shared publicationsM. Brandon Westover
Beacon Biosignals, United States
3 shared publications- Michael Brandon Westover
Harvard Medical School Boston Massachusetts USA
3 shared publications
Latest Publications
- Open Access
Characterization of Sleep, Spectral, and Epileptiform Activity in Individuals Aged 8–27 Years with SYNGAP1-Related Disorder Using an at-Home Dry EEG Headband
SYNGAP1-related disorder (SYNGAP1-RD) is associated with sleep disturbances, seizures, and neurophysiological abnormalities. However, in-lab EEG can be difficult to obtain due to the behavioral and sensory disorders associated with this condition. In this study we collected EEG in SYNGAP1-RD participants (n=30 enrolled, 27 contributing data) in a decentralized protocol using a dry electrode headband as a path to longitudinal, research-grade data collection in this population. At-home data collection was successful with 180 recordings containing over 1 hour of usable data collected from 23 participants. Across these recordings, sporadic interictal epileptiform discharges were present in 22 of 23 participants but electrographic seizures were not observed. Relative to an adolescent control population (n=10), SYNGAP1-RD participants showed increased wake after sleep onset, reduced sleep efficiency, and decreased time in N1 and N3 sleep stages along with increased time in N2. We reproduced prior findings from awake spectral EEG analyses, including elevated broadband power along with reduced relative alpha power and alpha-theta ratio in the SYNGAP1 cohort. Notably, differences in spectral power were tightly linked to sleep stage, revealing sleep-stage-dependent spectral biomarker dynamics not previously characterized in SYNGAP1-RD. Finally, we examined differences between variants producing truncations downstream of the GAP domain and those producing truncations before or within it, but analyses were limited by a small sample size (n=4 for the post-GAP variant). Overall, this study demonstrates the feasibility of at-home multi-night sleep EEG collection in participants with SYNGAP1-RD and led to both corroborative and novel findings.
Open AccessCharacterization of Sleep, Spectral, and Epileptiform Activity in Individuals Aged 8–27 Years with SYNGAP1-Related Disorder Using an at-Home Dry EEG Headband
SYNGAP1-related disorder (SYNGAP1-RD) is associated with sleep disturbances, seizures, and neurophysiological abnormalities. However, in-lab EEG can be difficult to obtain due to the behavioral and sensory disorders associated with this condition. In this study we collected EEG in SYNGAP1-RD participants (n=30 enrolled, 27 contributing data) in a decentralized protocol using a dry electrode headband as a path to longitudinal, research-grade data collection in this population. At-home data collection was successful with 180 recordings containing over 1 hour of usable data collected from 23 participants. Across these recordings, sporadic interictal epileptiform discharges were present in 22 of 23 participants but electrographic seizures were not observed. Relative to an adolescent control population (n=10), SYNGAP1-RD participants showed increased wake after sleep onset, reduced sleep efficiency, and decreased time in N1 and N3 sleep stages along with increased time in N2. We reproduced prior findings from awake spectral EEG analyses, including elevated broadband power along with reduced relative alpha power and alpha-theta ratio in the SYNGAP1 cohort. Notably, differences in spectral power were tightly linked to sleep stage, revealing sleep-stage-dependent spectral biomarker dynamics not previously characterized in SYNGAP1-RD. Finally, we examined differences between variants producing truncations downstream of the GAP domain and those producing truncations before or within it, but analyses were limited by a small sample size (n=4 for the post-GAP variant). Overall, this study demonstrates the feasibility of at-home multi-night sleep EEG collection in participants with SYNGAP1-RD and led to both corroborative and novel findings.
- Open Access
- 9 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184, 111182
At-home EEG-based sleep monitoring in people living with Lennox-Gastaut syndrome: The HEADFIRST study
- 9 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 184, 111182
Open AccessAt-home EEG-based sleep monitoring in people living with Lennox-Gastaut syndrome: The HEADFIRST study
- Open Access
- 28 March 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (7)
Multicenter evaluation of the Waveband system for automated sleep assessment in patients with insomnia symptoms
Study Objectives: This study (Octave-3) aimed to validate the performance of the Waveband dry-electroencephalography sensor device for automatic sleep staging and sleep parameter estimation as compared to gold-standard in-lab polysomnography (PSG). Methods: Forty-five participants were enrolled, and 38 completed simultaneous PSG and Waveband recordings. PSG data were scored by six human technologists, while Waveband data were scored algorithmically. Agreement between sleep staging results and derived sleep parameters (total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL), latency to 10 minutes of persistent sleep (LPS), wake after sleep onset (WASO), and time spent in each sleep stage) was measured using the Intraclass Correlation Coefficient (ICC) and overall agreement (OA). Waveband OA was compared to each human rater using the leave-one-out consensus of the remaining five human experts. Results: Average OA between Waveband vs the leave one out consensuses was 87.3+/-5.4 per cent, equivalent to the average OA for individual human experts of 85.9+/-7.6 per cent (p > .1). Waveband and humans had better OA over the second half of the night, but Waveband had superior OA. ICCs for TST, SE, LPS, and WASO exceeded 0.9, indicating excellent agreement between automated Waveband and human PSG scoring. Lower agreement was found for time spent in N1, N3, and Rapid Eye Movement Sleep (REM), with ICCs ranging from 0.65 to 0.73. Conclusions: Waveband provides accurate sleep staging and estimation of TST, SE, SOL, LPS, and WASO, with comparable performance to human expert staging of PSG. Its reduced form-factor and good performance should make it a valuable tool for automated assessment of sleep in patients with disturbed sleep. Clinical Trial Information Trial name: Octave-3. URL: https://www.clinicaltrials.gov/study/NCT05438017 Registration: NCT05438017.
- 28 March 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (7)
Open AccessMulticenter evaluation of the Waveband system for automated sleep assessment in patients with insomnia symptoms
Study Objectives: This study (Octave-3) aimed to validate the performance of the Waveband dry-electroencephalography sensor device for automatic sleep staging and sleep parameter estimation as compared to gold-standard in-lab polysomnography (PSG). Methods: Forty-five participants were enrolled, and 38 completed simultaneous PSG and Waveband recordings. PSG data were scored by six human technologists, while Waveband data were scored algorithmically. Agreement between sleep staging results and derived sleep parameters (total sleep time (TST), sleep efficiency (SE), sleep onset latency (SOL), latency to 10 minutes of persistent sleep (LPS), wake after sleep onset (WASO), and time spent in each sleep stage) was measured using the Intraclass Correlation Coefficient (ICC) and overall agreement (OA). Waveband OA was compared to each human rater using the leave-one-out consensus of the remaining five human experts. Results: Average OA between Waveband vs the leave one out consensuses was 87.3+/-5.4 per cent, equivalent to the average OA for individual human experts of 85.9+/-7.6 per cent (p > .1). Waveband and humans had better OA over the second half of the night, but Waveband had superior OA. ICCs for TST, SE, LPS, and WASO exceeded 0.9, indicating excellent agreement between automated Waveband and human PSG scoring. Lower agreement was found for time spent in N1, N3, and Rapid Eye Movement Sleep (REM), with ICCs ranging from 0.65 to 0.73. Conclusions: Waveband provides accurate sleep staging and estimation of TST, SE, SOL, LPS, and WASO, with comparable performance to human expert staging of PSG. Its reduced form-factor and good performance should make it a valuable tool for automated assessment of sleep in patients with disturbed sleep. Clinical Trial Information Trial name: Octave-3. URL: https://www.clinicaltrials.gov/study/NCT05438017 Registration: NCT05438017.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
Usability and stability of longitudinal at-home sleep evaluation using the Waveband electroencephalogram headband in an insomnia population
Study Objectives: Sleep monitoring outside of clinics could enhance care for insomnia and other sleep disorders but requires home systems that are easily operable and provide consistent data quality over multiple nights. We assessed the Waveband for usability by participants and feasibility of obtaining multi-night sleep data in the home setting. Methods: 15 subjects with insomnia wore the Waveband electroencephalogram headband and an FDA-cleared wearable home sleep testing device, WatchPAT ONE (“WP1”) for three nights. Usability was assessed via the System Usability Scale (SUS). Feasibility of participants to collect data was evaluated by examining stability of measured total sleep time in relation to measurements from the reference device (WP1) and data quality as evaluated by three human experts. Results: Average SUS score was 69.7, meeting the 68-point threshold for good usability. Total sleep time recorded by the Waveband and WP1 devices showed a correlation of 87.3 per cent. All the recordings had an average of over 7 scorable hours of data per night. Conclusions: Waveband demonstrated good usability by patients, was operable by patients, and generated interpretable data that provided stable sleep estimates across nights, comparable to an established home sleep testing device. The device has potential to advance patient care, sleep research, and clinical trials by enabling longitudinal ambulatory sleep assessment. Statement of Significance Home sleep testing is a valuable resource to provide accurate assessment of sleep in a person’s native environment. The ability to incorporate electroencephalogram (EEG) data into home sleep testing would be valuable for detailed assessment of sleep in a variety of neurological and psychiatric conditions with significant impacts on sleep. This study provides usability and feasibility data for the Waveband EEG headband, designed for patient use in the home environment to provide accurate EEG-based sleep staging. Results demonstrate that the Waveband device can be used by people without medical oversight to collect high quality data.
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
Open AccessUsability and stability of longitudinal at-home sleep evaluation using the Waveband electroencephalogram headband in an insomnia population
Study Objectives: Sleep monitoring outside of clinics could enhance care for insomnia and other sleep disorders but requires home systems that are easily operable and provide consistent data quality over multiple nights. We assessed the Waveband for usability by participants and feasibility of obtaining multi-night sleep data in the home setting. Methods: 15 subjects with insomnia wore the Waveband electroencephalogram headband and an FDA-cleared wearable home sleep testing device, WatchPAT ONE (“WP1”) for three nights. Usability was assessed via the System Usability Scale (SUS). Feasibility of participants to collect data was evaluated by examining stability of measured total sleep time in relation to measurements from the reference device (WP1) and data quality as evaluated by three human experts. Results: Average SUS score was 69.7, meeting the 68-point threshold for good usability. Total sleep time recorded by the Waveband and WP1 devices showed a correlation of 87.3 per cent. All the recordings had an average of over 7 scorable hours of data per night. Conclusions: Waveband demonstrated good usability by patients, was operable by patients, and generated interpretable data that provided stable sleep estimates across nights, comparable to an established home sleep testing device. The device has potential to advance patient care, sleep research, and clinical trials by enabling longitudinal ambulatory sleep assessment. Statement of Significance Home sleep testing is a valuable resource to provide accurate assessment of sleep in a person’s native environment. The ability to incorporate electroencephalogram (EEG) data into home sleep testing would be valuable for detailed assessment of sleep in a variety of neurological and psychiatric conditions with significant impacts on sleep. This study provides usability and feasibility data for the Waveband EEG headband, designed for patient use in the home environment to provide accurate EEG-based sleep staging. Results demonstrate that the Waveband device can be used by people without medical oversight to collect high quality data.
- 11 November 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (4)
The Insomnia EEG Score: a new tool for the classification of people with poor sleep
Quantitative features could help objectively identify and grade insomnia severity, though there is currently no pathophysiological biomarker of insomnia. In this study, we used the largest cohort of individuals with and without insomnia to date to train a model capable of distinguishing people with insomnia from those without insomnia. We identified 720 spectral, 606 spindle, and 16 macro-architecture features from electroencephalogram (EEG) channels of the polysomnography and examined their ability to classify people with insomnia and insomnia subtypes (subjective, maintenance, onset, and combined maintenance and onset), compared to individuals without insomnia. Consistent with prior work, these features poorly classified individuals when assessed independently. However, a linear combination of these features (the “Insomnia EEG Score” [IES]) was able to distinguish individuals with (N = 2123) and without (N = 930) insomnia, with spectral features providing the greatest discrimination (outperforming models based on hypnogram macroquantities or spindle features). These results demonstrate that insomnia is likely a quantifiable sleep disorder, albeit one requiring multiple objective measures (such as IES) to gauge disease subtype and, potentially, response to therapeutic interventions. Clinical Trials Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects with Insomnia Disorder, https://clinicaltrials.gov/study/NCT03545191, NCT03545191; Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering from Difficulties to Sleep, https://www.clinicaltrials.gov/study/NCT03575104, NCT03575104.
- 11 November 2025
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (4)
The Insomnia EEG Score: a new tool for the classification of people with poor sleep
Quantitative features could help objectively identify and grade insomnia severity, though there is currently no pathophysiological biomarker of insomnia. In this study, we used the largest cohort of individuals with and without insomnia to date to train a model capable of distinguishing people with insomnia from those without insomnia. We identified 720 spectral, 606 spindle, and 16 macro-architecture features from electroencephalogram (EEG) channels of the polysomnography and examined their ability to classify people with insomnia and insomnia subtypes (subjective, maintenance, onset, and combined maintenance and onset), compared to individuals without insomnia. Consistent with prior work, these features poorly classified individuals when assessed independently. However, a linear combination of these features (the “Insomnia EEG Score” [IES]) was able to distinguish individuals with (N = 2123) and without (N = 930) insomnia, with spectral features providing the greatest discrimination (outperforming models based on hypnogram macroquantities or spindle features). These results demonstrate that insomnia is likely a quantifiable sleep disorder, albeit one requiring multiple objective measures (such as IES) to gauge disease subtype and, potentially, response to therapeutic interventions. Clinical Trials Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects with Insomnia Disorder, https://clinicaltrials.gov/study/NCT03545191, NCT03545191; Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering from Difficulties to Sleep, https://www.clinicaltrials.gov/study/NCT03575104, NCT03575104.
- Open Access
- 5 February 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1428733
The role of sleep in Alzheimer’s disease: a mini review
Sleep is a stereotyped and well-preserved series of neurophysiological states that are essential for overall health and brain functioning. Emerging research suggests that sleep disturbances are not only associated with but also causally contribute to neurodegenerative disease onset and progression. This mini-review examines some of the current knowledge and evidence for relationships between sleep abnormalities and Alzheimer’s disease within context of possible uses and limitations of sleep biomarkers for evaluation of Alzheimer’s disease. Understanding these relationships could lead to readily accessible and easily quantifiable biomarkers of Alzheimer’s dementia.
- 5 February 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1428733
Open AccessThe role of sleep in Alzheimer’s disease: a mini review
Sleep is a stereotyped and well-preserved series of neurophysiological states that are essential for overall health and brain functioning. Emerging research suggests that sleep disturbances are not only associated with but also causally contribute to neurodegenerative disease onset and progression. This mini-review examines some of the current knowledge and evidence for relationships between sleep abnormalities and Alzheimer’s disease within context of possible uses and limitations of sleep biomarkers for evaluation of Alzheimer’s disease. Understanding these relationships could lead to readily accessible and easily quantifiable biomarkers of Alzheimer’s dementia.
- Open Access
- 9 June 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (1) , e14256
Hyperarousal features in the sleep architecture of individuals with and without insomnia
Summary: Sleep architecture encodes relevant information on the structure of sleep and has been used to assess hyperarousal in insomnia. This study investigated whether polysomnography‐derived sleep architecture displays signs of hyperarousal in individuals with insomnia compared with individuals without insomnia. Data from Phase 3 clinical trials, private clinics and a cohort study were analysed. A comprehensive set of sleep architecture features previously associated with hyperarousal were retrospectively analysed focusing on sleep–wake transition probabilities, electroencephalographic spectra and sleep spindles, and enriched with a novel machine learning algorithm called the Wake Electroencephalographic Similarity Index. This analysis included 1710 individuals with insomnia and 1455 individuals without insomnia. Results indicate that individuals with insomnia had a higher likelihood of waking from all sleep stages, and showed increased relative alpha during Wake and N1 sleep and increased theta power during Wake when compared with individuals without insomnia. Relative delta power was decreased and Wake Electroencephalographic Similarity Index scores were elevated across all sleep stages except N3, suggesting more wake‐like activity during these stages in individuals with insomnia. Additionally, sleep spindle density was decreased, and spindle dispersion was increased in individuals with insomnia. These findings suggest that insomnia is characterized by a dysfunction in sleep quality with a continuous hyperarousal, evidenced by changes in sleep–wake architecture.
- 9 June 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (1) , e14256
Open AccessHyperarousal features in the sleep architecture of individuals with and without insomnia
Summary: Sleep architecture encodes relevant information on the structure of sleep and has been used to assess hyperarousal in insomnia. This study investigated whether polysomnography‐derived sleep architecture displays signs of hyperarousal in individuals with insomnia compared with individuals without insomnia. Data from Phase 3 clinical trials, private clinics and a cohort study were analysed. A comprehensive set of sleep architecture features previously associated with hyperarousal were retrospectively analysed focusing on sleep–wake transition probabilities, electroencephalographic spectra and sleep spindles, and enriched with a novel machine learning algorithm called the Wake Electroencephalographic Similarity Index. This analysis included 1710 individuals with insomnia and 1455 individuals without insomnia. Results indicate that individuals with insomnia had a higher likelihood of waking from all sleep stages, and showed increased relative alpha during Wake and N1 sleep and increased theta power during Wake when compared with individuals without insomnia. Relative delta power was decreased and Wake Electroencephalographic Similarity Index scores were elevated across all sleep stages except N3, suggesting more wake‐like activity during these stages in individuals with insomnia. Additionally, sleep spindle density was decreased, and spindle dispersion was increased in individuals with insomnia. These findings suggest that insomnia is characterized by a dysfunction in sleep quality with a continuous hyperarousal, evidenced by changes in sleep–wake architecture.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Macro and microarchitectural features of sleep in Alzheimer’s dementia and mild cognitive impairment in a large clinical cohort
Background: Recent work has characterized polysomnographic changes in Alzheimer’s Dementia (AD) that correlate with disease severity and precede clinical diagnosis. However, relatively small sample sizes and a paucity of studies examining sleep microarchitecture have been limitations. In this study we examined sleep micro‐ and microarchitectural features in large cohorts of patients with AD and mild cognitive impairment (MCI).Method: Using a database of over 15,000 clinical PSGs with associated clinical metadata, 125 and 173 subjects were identified with mild AD and MCI, respectively. 260 age and sex matched subjects without neurological disease were identified as healthy controls (HC). Sleep staging results were based on AASM criteria, and micro‐architectural features were assessed using an algorithm trained to predict wake (1) or sleep (0) using spectral data from 3 seconds of EEG from a unique healthy adult cohort (Wake EEG Similarity Index, WESI).Result: Sleep fragmentation was apparent in both the MCI and AD cohorts (relative to healthy controls), with AD subjects demonstrating significantly more severe PSG disturbances. Healthy controls demonstrated 400 minutes of total sleep time, in contrast to 374 minutes for MCI subjects and 362 minutes for healthy controls. Healthy subjects demonstrated 33 minutes of wake after sleep onset (WASO), compared to 60 and 67 minutes for MCI and AD subjects, respectively. As has been previously reported in smaller cohorts, wakeful bouts and N1 durations were significantly prolonged for AD and (to a lesser extent) MCI subjects, while N2, N3, and REM durations were reduced (with a pronounced reduction in AD N3 percentage). Sleep microarchitectural features assessed using WESI demonstrated that AD and MCI subjects had markedly higher relative wakefulness in all sleep stages except for N3, which showed the same sleep depth as HC.Conclusion: We confirm increased sleep fragmentation and loss of deeper sleep stages, correlating to disease severity. Spectral features of all sleep stages EXCEPT N3 appear more wakeful in AD and MCI subjects ‐ suggesting microarousals or impaired sleep maintenance contribute to sleep pathology. While N3 duration was markedly reduced, depth of sleep was comparable between populations. PSG findings offer promise as early diagnostic and therapeutic targets.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S15)
Open AccessMacro and microarchitectural features of sleep in Alzheimer’s dementia and mild cognitive impairment in a large clinical cohort
Background: Recent work has characterized polysomnographic changes in Alzheimer’s Dementia (AD) that correlate with disease severity and precede clinical diagnosis. However, relatively small sample sizes and a paucity of studies examining sleep microarchitecture have been limitations. In this study we examined sleep micro‐ and microarchitectural features in large cohorts of patients with AD and mild cognitive impairment (MCI).Method: Using a database of over 15,000 clinical PSGs with associated clinical metadata, 125 and 173 subjects were identified with mild AD and MCI, respectively. 260 age and sex matched subjects without neurological disease were identified as healthy controls (HC). Sleep staging results were based on AASM criteria, and micro‐architectural features were assessed using an algorithm trained to predict wake (1) or sleep (0) using spectral data from 3 seconds of EEG from a unique healthy adult cohort (Wake EEG Similarity Index, WESI).Result: Sleep fragmentation was apparent in both the MCI and AD cohorts (relative to healthy controls), with AD subjects demonstrating significantly more severe PSG disturbances. Healthy controls demonstrated 400 minutes of total sleep time, in contrast to 374 minutes for MCI subjects and 362 minutes for healthy controls. Healthy subjects demonstrated 33 minutes of wake after sleep onset (WASO), compared to 60 and 67 minutes for MCI and AD subjects, respectively. As has been previously reported in smaller cohorts, wakeful bouts and N1 durations were significantly prolonged for AD and (to a lesser extent) MCI subjects, while N2, N3, and REM durations were reduced (with a pronounced reduction in AD N3 percentage). Sleep microarchitectural features assessed using WESI demonstrated that AD and MCI subjects had markedly higher relative wakefulness in all sleep stages except for N3, which showed the same sleep depth as HC.Conclusion: We confirm increased sleep fragmentation and loss of deeper sleep stages, correlating to disease severity. Spectral features of all sleep stages EXCEPT N3 appear more wakeful in AD and MCI subjects ‐ suggesting microarousals or impaired sleep maintenance contribute to sleep pathology. While N3 duration was markedly reduced, depth of sleep was comparable between populations. PSG findings offer promise as early diagnostic and therapeutic targets.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 2 (4) , e200101
Curriculum Innovation: Design and Implementation of Synchronous and Asynchronous Curricula to Enhance Residents' EEG Knowledge and Experience
Introduction and Problem Statement There is a need for structured EEG education opportunities to enhance neurology resident education. To address this need, the American Epilepsy Society (AES) supported the development and implementation of both synchronous and asynchronous EEG courses. Objectives To produce EEG curricula that enhance resident EEG learning, increase interest in EEG and improve participants9 knowledge, and to ensure that courses were highly used and available to the broadest range of learners. Methods and Curriculum Description A multi-institutional group of EEG educators developed both courses. The synchronous curriculum consisted of a mixture of brief “mini-lectures” and interactive small group activities with self-assessment quizzes at the start and end of the course. The online asynchronous EEG curriculum consisted of self-directed slide sets, multiple-choice self-assessment quizzes and a structured EEG self-assessment tool. Courses were evaluated using postcourse surveys, analysis of pretest and posttest data, and analysis of user data from the asynchronous curriculum. Results and Assessment Data Between 2019 and 2021, 56 residents participated in the synchronous EEG courses. On the resident survey, mean Likert scores for course design, planning, and learning outcomes ranged from 4.6 to 5.0 for the in-person courses and from 3.9 to 4.5 for the virtual course. On the 24-item pretests and posttests, overall median scores increased from 60% (14.5/24) to 75% (18/24; p < 0.001). More than 2,300 learners completed the first submodule of the asynchronous curriculum, but only 164 completed all sections. Most of those who completed the asynchronous curriculum reported that it was effective and appropriate for resident-level learning. Discussion and Lessons Learned The AES EEG courses provide EEG learning opportunities for neurology residents beyond what is available at their home institutions. There is evidence for the effectiveness of the synchronous course, but the scope is limited to a small number of attendees. The asynchronous curriculum is more broadly available, but very few learners completed all elements. Future steps will include expansion of the in-person synchronous course and providing guidance to learners about the core and optional components of the asynchronous curriculum to increase the impact of both educational offerings.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Education
- Vol. 2 (4) , e200101
Open AccessCurriculum Innovation: Design and Implementation of Synchronous and Asynchronous Curricula to Enhance Residents' EEG Knowledge and Experience
Introduction and Problem Statement There is a need for structured EEG education opportunities to enhance neurology resident education. To address this need, the American Epilepsy Society (AES) supported the development and implementation of both synchronous and asynchronous EEG courses. Objectives To produce EEG curricula that enhance resident EEG learning, increase interest in EEG and improve participants9 knowledge, and to ensure that courses were highly used and available to the broadest range of learners. Methods and Curriculum Description A multi-institutional group of EEG educators developed both courses. The synchronous curriculum consisted of a mixture of brief “mini-lectures” and interactive small group activities with self-assessment quizzes at the start and end of the course. The online asynchronous EEG curriculum consisted of self-directed slide sets, multiple-choice self-assessment quizzes and a structured EEG self-assessment tool. Courses were evaluated using postcourse surveys, analysis of pretest and posttest data, and analysis of user data from the asynchronous curriculum. Results and Assessment Data Between 2019 and 2021, 56 residents participated in the synchronous EEG courses. On the resident survey, mean Likert scores for course design, planning, and learning outcomes ranged from 4.6 to 5.0 for the in-person courses and from 3.9 to 4.5 for the virtual course. On the 24-item pretests and posttests, overall median scores increased from 60% (14.5/24) to 75% (18/24; p < 0.001). More than 2,300 learners completed the first submodule of the asynchronous curriculum, but only 164 completed all sections. Most of those who completed the asynchronous curriculum reported that it was effective and appropriate for resident-level learning. Discussion and Lessons Learned The AES EEG courses provide EEG learning opportunities for neurology residents beyond what is available at their home institutions. There is evidence for the effectiveness of the synchronous course, but the scope is limited to a small number of attendees. The asynchronous curriculum is more broadly available, but very few learners completed all elements. Future steps will include expansion of the in-person synchronous course and providing guidance to learners about the core and optional components of the asynchronous curriculum to increase the impact of both educational offerings.
- Open Access
Electroencephalographic insights into variant function and clinical outcomes in SCN2A encephalopathy
Neither phenotype nor genotype reliably predicts clinical disease severity or neurodevelopmental outcomes in SCN2A developmental and epileptic encephalopathy. In this study we examined the electroencephalographic (EEG) features of children with SCN2A variants to quantify the range of EEG abnormalities and link EEG biomarkers to developmental outcomes. We retrospectively analyzed data from a cohort of 28 children with SCN2A variants and employed a genetics-based consensus framework to infer the functional characterization of each subject’s SCN2A variant. Eleven subjects were predicted to have a gain-of-function variant, and 17 subjects a loss-of-function variant. Overall, variant classifications matched subject phenotypes. 493 EEG recordings from the 28 subjects were analyzed (ages 1 day to 16 years). In addition to the SCN2A recordings, normative data from 1230 children without an epilepsy diagnosis or epileptiform features based on neurologists’ review was analyzed (1704 EEG recordings, ages 0 days to 16 years). We detected interictal epileptiform discharges (IEDs) in the SCN2A recordings using Beacon’s automated IED detection algorithm. We characterized background spectral features by computing relative power in four frequency bands (delta=1-4Hz, theta=4-8Hz, alpha=8-13Hz, beta=13-30Hz) in recordings from both the SCN2A and control cohorts. Additionally, we determined whether each SCN2A recording was associated with a gross motor developmental delay based on reported attainment of gross motor milestones. We then used mixed effects logistic regression models to estimate the effect of EEG biomarkers on developmental delay. We characterized EEG abnormalities in the background spectral features of the SCN2A cohort compared to the controls and identified differences in EEG signatures between the subjects with gain- and loss-of-function variants. Additionally, we showed that background spectral features are correlated with motor developmental outcome when measured relative to age-matched neurotypical children. Furthermore, we showed that interictal epileptiform activity is correlated with delayed motor development in subjects with gain-of-function variants. Taken together, these findings suggest that EEG biomarkers can be used to identify neurological abnormalities that correlate both with SCN2A variants and measures of development. We demonstrate the potential value of EEG as a disease biomarker, and we highlight the potential of such biomarkers to both guide future invasive genetic therapies and to be used as diagnostic tools.
Open AccessElectroencephalographic insights into variant function and clinical outcomes in SCN2A encephalopathy
Neither phenotype nor genotype reliably predicts clinical disease severity or neurodevelopmental outcomes in SCN2A developmental and epileptic encephalopathy. In this study we examined the electroencephalographic (EEG) features of children with SCN2A variants to quantify the range of EEG abnormalities and link EEG biomarkers to developmental outcomes. We retrospectively analyzed data from a cohort of 28 children with SCN2A variants and employed a genetics-based consensus framework to infer the functional characterization of each subject’s SCN2A variant. Eleven subjects were predicted to have a gain-of-function variant, and 17 subjects a loss-of-function variant. Overall, variant classifications matched subject phenotypes. 493 EEG recordings from the 28 subjects were analyzed (ages 1 day to 16 years). In addition to the SCN2A recordings, normative data from 1230 children without an epilepsy diagnosis or epileptiform features based on neurologists’ review was analyzed (1704 EEG recordings, ages 0 days to 16 years). We detected interictal epileptiform discharges (IEDs) in the SCN2A recordings using Beacon’s automated IED detection algorithm. We characterized background spectral features by computing relative power in four frequency bands (delta=1-4Hz, theta=4-8Hz, alpha=8-13Hz, beta=13-30Hz) in recordings from both the SCN2A and control cohorts. Additionally, we determined whether each SCN2A recording was associated with a gross motor developmental delay based on reported attainment of gross motor milestones. We then used mixed effects logistic regression models to estimate the effect of EEG biomarkers on developmental delay. We characterized EEG abnormalities in the background spectral features of the SCN2A cohort compared to the controls and identified differences in EEG signatures between the subjects with gain- and loss-of-function variants. Additionally, we showed that background spectral features are correlated with motor developmental outcome when measured relative to age-matched neurotypical children. Furthermore, we showed that interictal epileptiform activity is correlated with delayed motor development in subjects with gain-of-function variants. Taken together, these findings suggest that EEG biomarkers can be used to identify neurological abnormalities that correlate both with SCN2A variants and measures of development. We demonstrate the potential value of EEG as a disease biomarker, and we highlight the potential of such biomarkers to both guide future invasive genetic therapies and to be used as diagnostic tools.